



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH
REPUBLIC

Best of ASTRO 2019

Czech Republic

23.3. 2020

Clarion Congress Hotel Olomouc





SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH REPUBLIC

09:15 - 09:30 **Welcome**

09:30 - 10:15 **Track 1 – Gastrointestinal (Renata Soumarova)**

Abstract 1: (175) A Pilot Study of Neoadjuvant FOLFIRINOX followed by Chemoradiation for Gastric and Gastroesophageal Cancer: Preliminary Results and Prognostic Implications of ctDNA

Abstract 2: (176) Patterns of Recurrence in the Critics Gastric Cancer Trial: Results from Intention-to-Treat and per-Protocol Analyses

Abstract 3: (215) The Genomic Landscape of Anal Cancer and Its Relationship to Clinical Outcomes: An Exploratory Analysis of NRG Oncology/RTOG 98-11

Abstract 4: (217) ctDNA As a Potential Prognostic Marker for Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Chemo-Radiation Therapy on Disease- Free Survival (DFS)

Abstract 5: (218) Patient-Derived Organoids (PDO) As the Potential Model to Predict Treatment Outcome of Rectal Cancer Patients Underwent Neo-Adjuvant Chemoradiotherapy

Abstract 6: (219) Improved Stratification for Risk of Early Metastases by Baseline Circulating Tumor Cell Counts for Locally Advanced Rectal Cancer in Neoadjuvant Setting: an Exploratory Analysis from a Phase III trial

Abstract 7: (227) Multicenter Phase II Study of Stereotactic Ablative RadioTherapy for Hepatocellular Carcinoma ≤ 5 cm (KROG 12-02)

Abstract 8: (229) Evaluating the Impact of Combination of Nivolumab and Ipilimumab to Liver/Lung SBRT on Local Control for Colorectal and Pancreatic Cancer: A Pooled Analysis of Two Prospective Trials



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH
REPUBLIC

10:15 - 11:00 **Track 2 – Gynecological (Martin Dolezel)**

Abstract 1: (2) Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer

Abstract 2: (101) IMRT Improves Late Toxicity Compared to Conventional RT: An Update on NRG Oncology- RTOG 1203

Abstract 3: (104) Sexual Activity and Vaginal Functioning in Patients with Locally Advanced Cervical Cancer following Definitive Radiochemotherapy and Image-Guided Adaptive Brachytherapy (EMBRACE Study)

Abstract 4: (105) Comparison of Concurrent Cisplatin Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer

Abstract 5: (103) Nomograms Predicting Overall Survival in Locally Advanced Cervical Cancer treated by Image Guided Brachytherapy: a Retro-EMBRACE study

Abstract 6: (1237) Definitive External Beam Radiation Therapy With Stereotactic Body Radiation Therapy Boost for FIGO Stage IB - IIB Cancer of the Cervix: Minimum 5-Year Disease Control, Toxicity and Quality of Life Outcomes From a Phase 2 Trial

Abstract 7: (1242) Regional Control and Dose-Response for Chemoradiotherapy in Locally-Advanced Endometrial Cancer

Abstract 8: (1238) Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality Treatment



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH
REPUBLIC

11:10 - 12:00 **Track 3 – Genitourinary (Karel Odrázka)**

Abstract 1: (77) A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP “RAVES” Trial

Abstract 2: (112) Accelerating Prostate Stereotactic Ablative Body Radiotherapy (SABR): Efficacy and Toxicity of a Randomized Phase II Study of 11 Versus 29 Days Overall Treatment Time (PATRIOT Study; ClinicalTrials.gov NCT01423474)

Abstract 3: (115) A Biochemical Definition of Cure Following Brachytherapy for Prostate Cancer: A Multi- Institution International Study

Abstract 4: (1050) Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and Bcon Trials

Abstract 5: (111) Patient Reported Acute Toxicity in PACE-B, an International Phase III Randomised Controlled Trial Comparing Stereotactic Body Radiotherapy to Conventionally Fractionated or Moderately Hypofractionated Radiotherapy (CFMHRT) for Localised Prostate Cancer

Abstract 6: (113) High Dose-Rate Prostate Brachytherapy as Monotherapy: a Single Fraction May Not be Enough

Abstract 7: (82) Development and Validation of the First AJCC Compliant Clinical Staging System for Localized Prostate Cancer: Results from a Multicenter International Study

Abstract 8: (81) Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost: Comparison of Outcomes in A Multi-Institutional Analysis of 4,086 Patients with High-Risk Prostate Cancer

Abstract 9: (LBA 1) Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH
REPUBLIC

12:00 - 12:30 **Track 4 – Breast (Jiri Petera)**

Abstract 1: (5) Cosmetic Outcome from Post Lumpectomy Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) on the NRG Oncology/NSABP B39- RTOG 0413 Phase III Clinical Trial

Abstract 2: (85) Quantifying the Impact of Regional Lymph Node Irradiation on Lymphedema Risk in Breast Cancer Patients Treated with SLNB or ALND: Long- Term Results from a Prospective Screening Trial

Abstract 3: (84) Prospective Phase II Clinical Trial of Hypofractionated Radiation in Breast Cancer Patients undergoing Comprehensive Nodal Irradiation for Node Positive Disease

Abstract 4: (87) A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC)

Abstract 5: (18) Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the NCCTG N9831 (Alliance) Study

Abstract 6: (83) Post Mastectomy Radiation Therapy in HER2/ neu Positive Breast Cancer: Analysis of the HERA trial



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH
REPUBLIC

13:30 - 14:00 **Track 5 – Best of the Rest (Martin Doležel)**

Abstract 1: (1) PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSG

Abstract 2: (69) Radiotherapy in Early-Stage Gastric MALT: Improved Survival without Increased Cardiac Death

Abstract 3: (11) The Low-Dose Bath Paradox: Do Spatial Irradiation Patterns Play a Role in the Incidence of Radiation Pneumonitis Following PSPT or IMRT?

Abstract 4: (63) Acute Toxicity Patterns in Adaptive High Precision Radiotherapy for Head and Neck Cancer - a Randomised Controlled Trial

Abstract 5: (98) A Prospective Randomized Phase II Trial of Single-Fraction versus Multi-Fraction Stereotactic Spine Radiosurgery for Spinal Metastases: An Initial Analysis

Abstract 6: (100) Single-Fraction Stereotactic versus Conventional Multifraction Radiation for Predominantly Non-Spine Bone Metastases: A Randomized Phase II Trial

Abstract 7: (148) Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial

14:00 - 14:30 **Track 6 – Oligometa (Jakub Cvek)**



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH
REPUBLIC

14:30 - 15:00 **Track 7 – Lung (David Feltl)**

Abstract 1: (71) The Incidence and Location of Brain Metastases Following HA-PCI Compared with Standard PCI in Small Cell Lung Cancer (SCLC): A Phase III Trial

Abstract 2: (72) Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for SMALLCELL LUNG Cancer.

Abstract 3: (73) A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer

Abstract 4: (90) Accelerated Hypofractionated CRT Followed by SABR Boost (HyCRT-SABR) for Locally Advanced Unresectable NSCLC: A Prospective Phase II Radiation Dose Escalation Study

Abstract 5: (91) Left Coronary Artery Dose Exposure Predicts Major Adverse Cardiac Events in Coronary Heart Disease Negative Lung Cancer Patients

Abstract 6: (92) The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Elderly Stage III Non-Small Cell Lung Cancer Treated with Definitive Chemoradiation



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH REPUBLIC

15:15 - 16:00 **Track 8 – Head and Neck (Milan Vosmik)**

Abstract 1: (106) Radiotherapy vs. Trans-Oral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma (OPSCC): Results of a Randomized Trial

Abstract 2: (107) A Phase II Trial of Alternative Volumes of Oropharyngeal Irradiation for Deintensification (AVOID): Omission of the Resected Primary Tumor Bed for Squamous Cell Carcinoma of the Oropharynx

Abstract 3: (31) Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma; Update of the Long-Term Tumor Control of a Randomized Clinical Trial

Abstract 4: (108) Recurrence and Quality-of-Life Following Elective Nodal Volume and Dose De-Escalation for Oropharyngeal and Laryngeal Cancer: Initial Results from the Infield Trial

Abstract 5: (109) Randomized Clinical Trial on 7-days-a-week Postoperative Radiotherapy vs. Concurrent Postoperative Radio-chemotherapy in Locally Advanced Cancer of the Oral Cavity/Oropharynx

Abstract 6: (32) Stem Cell Sparing IMRT for Head and Neck Cancer Patients: A Double-Blind Randomized Controlled Trial

Abstract 7: (34) Cost-Effectiveness of Screening for Nasopharyngeal Carcinoma with Serology or Plasma Epstein Barr-Virus DNA in High-Incidence Populations Globally

Abstract 8: (37) A Pilot Study of Stereotactic Body Radiotherapy (SBRT) Combined with a PD-L1 Antibody Durvalumab (D) and a CTLA-4 antibody Tremelimumab (T) To Treat Metastatic Anaplastic Thyroid Cancer (ATC)

Abstract 9: (LBA 5) Detectable HPV ctDNA in Post-Operative Oropharyngeal Squamous Cell Carcinoma Patients is Associated with Progression

Abstract 10: (LBA 10) NRG-HN002: A Randomized Phase II Trial for Patients with p16-Positive, Non- Smoking-Associated, Locoregionally Advanced Oropharyngeal Cancer



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH
REPUBLIC

16:00 - 16:45 **Track 9 – Central Nervous System (Tomas Kazda, Pavel Slampa)**

Abstract 1: (3) Radiosurgery Compared to External Beam Radiotherapy for Localized Spine Metastasis: Phase III Results of NRG Oncology/RTOG 0631

Abstract 2: (23) Significant Preservation of Neurocognitive Function (NCF) and Patient-Reported Symptoms with Hippocampal Avoidance (HA) during Whole- Brain Radiotherapy (WBRT) for Brain Metastases: Final Results of NRG Oncology CC001

Abstract 3: (160) Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report

Abstract 4: (161) Comprehensive Prognostic and Predictive Molecular Subgroup Analysis within the High-risk Treatment Arms of NRG Oncology/RTOG 9802: A Phase III Trial of RT versus RT + PCV in High-risk Low-grade Gliomas

Abstract 5: (20) Prospective Phase I Dose Escalation Study for Neoadjuvant Radiosurgery for Large Brain Metastases

Abstract 6: (163) Microstructural Injury to Perisylvian White Matter Predicts Language Decline After Brain Radiotherapy [RT]: Quantitative Analysis of a Prospective Trial

Abstract 7: (1056) A Single Blind Randomized Controlled Trial of Hippocampal Avoidance on Neurocognitive Outcomes After Conformal Whole Brain Radiotherapy for Brain Metastases: An Initial Analysis

Abstract 8: (MO_4_2176) Leucencephalopathy after Prophylactic Whole Brain Irradiation with or without Hippocampal Sparing: A Long-Term MRI Analysis



SCIENCE OF TODAY
HOPE FOR TOMORROW

CZECH REPUBLIC

Contact: dolezelm@email.cz, BoACR@fnol.cz

Doc. MUDr. Martin Doležel, Ph.D.
Onkologická klinika FN Olomouc
779 00 Olomouc

Clarion Congress Hotel Olomouc
<https://www.clarioncongresshotelolomouc.com>
Jeremenkova 36, 779 00 Olomouc, Česká republika
GPS: 49°35'33.130"N 17°16'32.721"E

Vzdělávací akce je pořádána dle Stavovského předpisu ČLK č.16,
bude ohodnocena příslušným počtem kreditů.

Výše účastnického poplatku je 150 Kč (platba na místě).

Prosím o elektronické přihlášení na email (BoACR@fnol.cz),
nejpozději do **16. 3. 2020**.